$GERN Must Read, Updated Chart

$GERN Must Read, Updated Chart



About Us

We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF), and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under the terms of an exclusive worldwide collaboration and license agreement.

The role of telomerase and the potential implications for cancer have been a focus of Geron since our founding. The discovery and early development of imetelstat, our sole product candidate, was based on our core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using our proprietary nucleic acid chemistry, we designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in myelofibrosis (MF), suggest imetelstat may have disease-modifying activity by inhibiting the proliferation of malignant progenitor cell clones for the underlying diseases.

Our Pipeline

Imetelstat, a first-in-class telomerase inhibitor and our sole product candidate, is being developed for the potential treatment of hematologic myeloid malignancies. Imetelstat is currently in two clinical trials being conducted by Janssen under the terms of an exclusive worldwide collaboration and license agreement.



Our Culture

Our corporate culture reflects a history of innovation, collaboration and perseverance.

We are driven by a shared vision to develop novel therapies for patients with cancer, as well as by the passion and personal goals of our employees. Our vision can only be accomplished through the talent we bring into and retain in the company, and the culture and values we embody as a team. We recognize and value the unique strengths of our team members, and the impact and contributions of each employee.

Geron’s corporate values are the essential tenets that guide our decisions, govern our relationships with each other and our partners, and articulate what we stand for and who we are. These values dictate the ways in which we interact, work and communicate, how we resolve conflicts and ultimately how we strive to make Geron successful.

Authenticity – Having well-intentioned interactions that are genuine and real.

Accountability – Taking responsibility for our actions, including decisions, and the effect they have on the company.

Excellence – Having relentlessly high standards.

Integrity – Behaving ethically in all situations and demanding the same from others.

Respect – Valuing our co-workers’ and partners’ feelings, needs, ideals, time and preferences.